Get the Stockscreener App
38.77
0.77%
-0.30
After Hours:
38.77
Calliditas Therapeutics AB ADR stock is currently priced at $38.77, with a 24-hour trading volume of 4,268.
It has seen a -0.77% decreased in the last 24 hours and a +71.62% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $39.14 pivot point. If it approaches the $38.60 support level, significant changes may occur.
Previous Close:
$39.07
Open:
$39
24h Volume:
4,268
Market Cap:
$1.04B
Revenue:
$135.65M
Net Income/Loss:
$-26.43M
P/E Ratio:
-34.90
EPS:
-1.111
Net Cash Flow:
$-31.04M
1W Performance:
-1.82%
1M Performance:
+71.62%
6M Performance:
+86.84%
1Y Performance:
+117.25%
1D Range:
$38.68
$39.00
52W Range:
$15.25
$41.90
Calliditas Therapeutics AB ADR Stock (CALT) Company Profile
Name
Calliditas Therapeutics AB ADR
Sector
Industry
Phone
46 84 11 30 05
Address
Kungsbron 1, C8, Stockholm
Calliditas Therapeutics AB ADR Stock (CALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-20-23 | Initiated | H.C. Wainwright | Buy |
| Mar-01-23 | Initiated | Guggenheim | Neutral |
| Feb-26-21 | Initiated | H.C. Wainwright | Buy |
| Jul-01-20 | Initiated | Citigroup | Buy |
| Jun-30-20 | Initiated | Jefferies | Buy |
Calliditas Therapeutics AB ADR Stock (CALT) Latest News
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Large Volume Increase - Defense World
Defense World
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Unusually-High Trading Volume - MarketBeat
MarketBeat
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Hits New 52-Week High at $40.49 - MarketBeat
MarketBeat
Short Interest in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Rises By 12.6% - MarketBeat
MarketBeat
Calliditas Therapeutics AB Sponsored ADR (CALT) Moves 12.8% Higher: Will This Strength Last? - Yahoo Movies Canada
Yahoo Movies Canada
Calliditas Therapeutics AB (publ)'s (CALT) “Neutral” Rating Reaffirmed at Citigroup - Defense World
Defense World
Calliditas Therapeutics AB ADR Stock (CALT) Financials Data
Calliditas Therapeutics AB ADR (CALT) Revenue 2024
CALT reported a revenue (TTM) of $135.65 million for the quarter ending December 31, 2023, a +237.28% rise year-over-year.
Calliditas Therapeutics AB ADR (CALT) Net Income 2024
CALT net income (TTM) was -$26.43 million for the quarter ending December 31, 2023, a +60.89% increase year-over-year.
Calliditas Therapeutics AB ADR (CALT) Cash Flow 2024
CALT recorded a free cash flow (TTM) of -$31.04 million for the quarter ending December 31, 2022, a +42.44% increase year-over-year.
Calliditas Therapeutics AB ADR (CALT) Earnings per Share 2024
CALT earnings per share (TTM) was -$0.983 for the quarter ending December 31, 2023, a +61.74% growth year-over-year.
About Calliditas Therapeutics AB ADR
Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden.
0.87%
0.21%
Cap:
|
Volume (24h):